Guest guest Posted December 3, 2002 Report Share Posted December 3, 2002 Pharmagene begins Phase I study on cystic fibrosis therapy DATELINE: LONDON Pharmagene PLC said it has begun a Phase I study with PGN52, its cystic fibrosis product, in healthy volunteers. PGN52, a synthetic version of the human peptide hormone, secretin, which is used as an aerosol, has potential therapeutic benefit in cystic fibrosis by promoting liquid secretions in the lungs, the company added. It said PGN52 was well tolerated in a broad range of pre-clinical toxicology studies. Phase II studies in patients are scheduled to commence in the second half of 2003. Becki YOUR FAVORITE LilGooberGirl YOUNGLUNG EMAIL SUPPORT LIST www.topica.com/lists/younglung Pediatric Interstitial Lung Disease Society http://groups.yahoo.com/group/InterstitialLung_Kids/ Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.